The startup operates a robotic healthcare platform that utilizes intact gastrointestinal tract tissue for fully automated drug testing. This technology enhances the efficacy, safety, and adherence of existing and novel therapies for healthcare providers.
Funding
$4.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many biologic drugs cannot be administered orally due to poor bioavailability, limiting their therapeutic potential and requiring administration via injection. This poses challenges for patient compliance and can lead to increased healthcare costs.
Solution
Vivtex is developing next-generation oral therapeutics by leveraging its proprietary GI-ORIS™ (Gastrointestinal Organ Robotic Interface System) technology. This platform enables high-throughput, fully automated robotic screening using intact gastrointestinal tract tissue to identify optimal drug candidates and delivery systems that maximize oral bioavailability. By creating custom drug delivery systems, Vivtex aims to reformulate existing injectable drugs for oral administration and develop new orally bioavailable therapeutics in partnership with pharmaceutical and biotechnology companies. The platform utilizes AI capabilities to enhance the identification of drug candidates with maximal GI absorption, avoiding the need for needle injections.
Target Audience
Vivtex partners with pharmaceutical and biotechnology companies to develop new oral therapeutics and reformulate existing injectable drugs.
Features
- GI-ORIS™ robotic screening technology maintains porcine GI tissue integrity for high-throughput studies.
- Large library of oral drug delivery systems for systematic identification of optimal drug candidates.
- AI-driven analysis to identify drug candidates with maximal GI absorption.
- Capabilities for reformulating existing injectable drugs for oral administration.
- Development of custom drug delivery systems to enhance oral bioavailability.